Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT02145390 Terminated - Bladder Cancer Clinical Trials

Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy

Start date: January 5, 2016
Phase: N/A
Study type: Interventional

Bladder preservation in patients with complete response after neoadjuvant chemotherapy will lead to equivalent or superior relapse free rates compared to cystectomy rates from historical controls.

NCT ID: NCT02138578 Terminated - Clinical trials for Renal Cell Carcinoma

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

Start date: May 2014
Phase: N/A
Study type: Interventional

This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell carcinomas.

NCT ID: NCT02137252 Terminated - Clinical trials for Ductal Carcinoma in Situ

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Start date: May 2014
Phase: Phase 2
Study type: Interventional

Naltrexone is a drug which blocks some effects of chemicals called beta-endorphins that are made in the body. Beta-endorphins can be made in response to stress, injury, and also pleasurable activities. In previous studies, it has been shown that levels of beta-endorphins in the blood go up during radiation therapy, and that this increase is linked to fatigue. This suggests that naltrexone may help to reduce fatigue in people who are getting radiation therapy In this research study, the investigators are looking to see whether naltrexone works better than a placebo in reducing fatigue during radiation therapy.

NCT ID: NCT02137096 Terminated - Clinical trials for Recurrent Nasopharynx Carcinoma

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Start date: June 2014
Phase: Phase 3
Study type: Interventional

This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.

NCT ID: NCT02127073 Terminated - Breast Cancer Clinical Trials

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer

Start date: January 30, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the genetic material called microRNA of three types of specimens from women with breast cancer. The study also seeks to examine the effectiveness of using a new agent called oxytocin to increase the amount of nipple fluid that can be collected during surgery.

NCT ID: NCT02122003 Terminated - Clinical trials for Metastatic Renal Cell Carcinoma

Second Line Sorafenib After Pazopanib in Patients With RCC

SOAP
Start date: September 2016
Phase: Phase 2
Study type: Interventional

- Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). - Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for metastatic Renal Cell Carcinoma (mRCC). - With this trial we evaluate the efficacy of sorafenib as second line of treatment in patients treated with pazopanib for mRCC.

NCT ID: NCT02107378 Terminated - Clinical trials for Epithelial Ovarian Carcinoma

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).

NCT ID: NCT02102022 Terminated - Colorectal Cancer Clinical Trials

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).

NCT ID: NCT02094560 Terminated - Clinical trials for Advanced Endstage Solid Carcinomas in Adults

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors

CAP7-1
Start date: November 8, 2011
Phase: Phase 2
Study type: Interventional

To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma (NSCLC), SCLC or biliary cancer who have progressed despite one or more previous chemotherapy line.

NCT ID: NCT02089802 Terminated - Clinical trials for Metastatic Renal Cell Carcinoma

Optimizing Pazopanib Exposure in RCC Patients

OPERA
Start date: February 25, 2014
Phase: Phase 2
Study type: Interventional

Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.